Celltrion(068270) is expanding its influence as it maintains the No. 1 share of prescriptions for autoimmune and anticancer therapies in major Asian markets. The company will begin full-scale launches of high-margin follow-up products based on the performance of existing products.
According to IQVIA, a pharmaceutical market research firm, on the 19th, in the first quarter of this year Celltrion's autoimmune disease therapy "Remsima" (ingredient Infliximab) ranked No. 1 in each country with a 93% share in Singapore, 84% in Hong Kong, 78% in Thailand, and 72% in Malaysia.
Anticancer drugs also stayed at the forefront in major markets. The hematologic cancer therapy "Truxima" (Rituximab) ranked No. 1 with a 93% share in Singapore and 78% in Thailand, while the breast and gastric cancer therapy "Herzuma" (Trastuzumab) posted a 51% share in Malaysia and 42% in Thailand.
In particular, in Malaysia, growth of the metastatic colorectal and breast cancer therapy "Vegzelma" (Bevacizumab) stood out. Vegzelma, which was No. 4 by share among local Bevacizumab products in the fourth quarter of last year, climbed to No. 1 in just one quarter with a 30% share in the first quarter of this year.
Celltrion operates a direct sales system through local subsidiaries in major Asian countries, including Malaysia, Singapore, and Thailand. It is working to expand prescriptions for its products based on sales tailored to each country's bidding environment and a stable supply.
New product launches will also continue. Celltrion plans to launch the allergy therapy "OMLYCLO" (Omalizumab) and the bone disease therapy "Stoboclo-Ossenbelt" (Denosumab) in Thailand in the second half of this year. In Malaysia and Singapore, it will introduce the autoimmune disease therapy "Steqeyma" (Ustekinumab) within the year.
A Celltrion official said, "Major product lines, including Remsima, continue to hold the No. 1 share in key Asian countries, increasing their market influence," and added, "We will carry the performance of existing products into new products to drive both sales growth and improved profitability in Asia."